Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 24Neoplasm Metastasis 2Urogenital Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Radiation Injuries 1Prostatic Diseases 1Prostate Adenocarcinoma 1PSA Level Greater Than 0.03 1Oligorecurrent and Oligoprogressive Prostate Cancer Patients 1Neoplasms 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1

Interventions

bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Radiosurgery 2Leuprolide 2Goserelin 2relugolix 1radium Ra 223 dichloride 1luprolide acetate gel depot 1histrelin 1flibanserin 1darolutamide 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radiotherapy 1Radiation 1Proton Therapy 1Magnetic Resonance Spectroscopy 1Flutamide 1Buserelin 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostate Adenocarcinoma × Androgen Antagonists × Clear all
NCT04743934 2025-05-04

RAD 2003

University of Alabama at Birmingham

Phase 2 Active not recruiting
44 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡